arrow
Z

Zheng Tang

fudan university
H指数:24
被引数:1,763

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction to “Laser-Induced Combinatorial Chemotherapeutic; Chemodynamic; and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal–Organic Frameworks”

更正“基于奥沙利铂负载金属-有机框架的激光诱导组合化疗;化学动力学疗法;及光热疗法用于肝细胞癌”

2025-10-130
OAAI
Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation

中性粒细胞与淋巴细胞比值在重复肝切除或挽救性肝移植后复发性肝癌中的预测价值

2025-02-220
PRE
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells

靶向SRSF1通过双重作用于CD8+T细胞和肿瘤细胞来改善癌症免疫治疗

2025-01-224
OA
Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming

癌症相关成纤维细胞通过CD36-mediated脂肪酸代谢重编程促进肝细胞癌复发和转移

2024-02-0112
PRE
Single-cell and spatial architecture of primary liver cancer
2023-11-2011
OAAI
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation

预测肝移植后肝癌复发的深度病理学评分的建立

2023-04-0822
OAAI
CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor

CD36癌相关成纤维细胞通过分泌巨噬细胞移动抑制因子为肝细胞癌提供免疫抑制微环境

2023-03-06118
OAAI
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

使用toripalimab,lenvatinib和TACE联合治疗最初无法切除的肝细胞癌的转化治疗: 真实世界研究

2022-09-2046
OAAI